Zymeworks Acquires Theravance
Zymeworks to Acquire Theravance Biopharma for $929 Million, Boosting Cash Flow with Yupelri
Anonymous
Key Points
1
Theravance Biopharma disclosed a termination fee of 32.5 million in connection with the acquisition offer by Zymeworks.
2
Zymeworks will secure a 35% U.S. net profit share in Yupelri, which posted 266.6 million in U.S. net sales in 2025.
3
Financing is structured as a non-recourse arrangement secured solely by Yupelri’s U.S. profit share (via OMERS Life Sciences) and Theravance’s expected net cash balance at closing, with a TRELEGY ELLIPTA milestone anticipated in Q1 2027 to offset cash outlay.
4
Beyond Yupelri, the deal adds diversified assets including additional royalty interests, milestone payments, a preclinical I&I portfolio, and Irish tax attributes, strengthening near-term cash flow generation and long-term development optionality.
5
YUPELRI (revefenacin) is the first and only approved nebulized long-acting muscarinic antagonist (LAMA) for COPD maintenance, with U.S. marketing previously conducted through Theravance's collaboration with Viatris.
Zymeworks has agreed to buy Theravance Biopharma for $929 million in cash, or $17 per share, marking a dramatic pivot from pure oncology into respiratory disease. The deal, announced June 29, 2026, gives Zymeworks a 35% share of U.S. profits from Yupelri, a COPD drug that posted $266.6 million in U.S. net sales in 2025, according to GlobeNewswire.
The $17 price tag represents a 22% premium over Theravance's closing price on March 3, 2026, the day the company announced it was laying off half its workforce after a key drug trial failed, Endpoints News reported.
A Clever Deal Structure Limits Zymeworks' Cash at Risk
Zymeworks is not writing a $929 million check out of pocket. Instead, the deal is financed in three parts: a $350 million loan from OMERS Life Sciences secured only against Yupelri's future profit share, $360 million in cash Theravance is expected to hold at closing, and $219 million from Zymeworks' own balance sheet, according to BioXconomy.
A $100 million milestone payment from Royalty Pharma, tied to Trelegy Ellipta sales and expected in Q1 2027, will effectively cancel out most of Zymeworks' $219 million cash outlay. That leaves Zymeworks' true net cost at roughly $119 million, Pharmaphorum noted. The loan from OMERS is non-recourse, meaning Zymeworks' broader assets are not on the hook if Yupelri underperforms.
Yupelri Is the Crown Jewel — and It Keeps Growing
Yupelri (revefenacin) is the first and only FDA-approved nebulized LAMA — a type of inhaled COPD maintenance drug — on the U.S. market. It recorded $266.6 million in U.S. net sales in 2025, up 12% year-over-year, and generated $62.4 million in Q1 2026 alone. Viatris handles community promotion while Theravance runs a hospital sales team that Zymeworks plans to keep largely intact, Endpoints News reported.
Generic drug settlements protect Yupelri's exclusivity until April 2039, giving Zymeworks a long runway. The profit share and ex-U.S. royalties together generate roughly $60 million in annualized cash flow, according to Stock Titan. Management says the deal will be immediately accretive — meaning it adds to earnings right away.
Theravance's Long Road Down Before the Buyout
Theravance's sale came after years of struggle. In early 2024, its board formed a Strategic Review Committee and hired Lazard to explore options for unlocking value, according to Investing.com. Then in March 2026, the company's lead experimental drug, ampreloxetine, failed to hit its primary goal in a key clinical trial. Theravance responded by cutting 50% of its staff and shutting its R&D operations.
Theravance shareholders will get one Contingent Value Right (CVR) on top of the $17 cash. If Zymeworks licenses or sells ampreloxetine within 12 months of closing, shareholders receive 80% of those proceeds. Theravance's board unanimously backed the deal. A termination fee of $32.5 million applies if either side walks away under specific conditions, per SEC filings.
Zymeworks Bets on a New Identity: Part Innovator, Part Cash Machine
Kenneth Galbraith, Zymeworks' CEO, called the acquisition "a compelling opportunity to accelerate our strategy by adding high-quality commercial and late-stage assets" to build "a more diversified and durable business." The deal adds Theravance's Irish tax attributes, valued at $2.5 billion, alongside royalty interests and milestone payments that broaden Zymeworks' revenue base well beyond its core antibody-drug conjugate program, Ziihera.
Endpoints News framed the deal as Zymeworks "putting Theravance out of its misery," while analysts at Investing.com noted the $17 price may be fair but not generous — Theravance stock fell roughly 2.5% in premarket trading after the news. The deal still needs approval from two-thirds of Theravance shareholders and U.S. antitrust clearance. Closing is expected in Q3 or Q4 2026.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
19
Articles
120
Reach
139
A
AnonymousAuthor
